Table 3.
Baseline characteristics of the participantsa
| Placebo group | CP1563 group | ||
|---|---|---|---|
| (n=100) | (n=100) | ||
| Male | 50 | 50 | |
| Female | 50 | 50 | |
| Age | (y) | 46.6±11.9 | 46.2±12.0 |
| Body weight | (kg) | 76.4±9.5 | 76.7±9.6 |
| Height | (cm) | 163.6±9.3 | 164.3±9.4 |
| Body mass index | (kg/m2) | 28.3±1.6 | 28.5±1.6 |
| Waist circumference | (cm) | 97.6±4.8 | 98.0±4.8 |
| Hip circumference | (cm) | 100.4±4.0 | 101.5±4.1 |
| Visceral fat area | (cm2) | 109.4±35.6 | 106.9±35.9 |
| Subcutaneous fat area | (cm2) | 277.5±63.0 | 285.9±63.6 |
| Whole body fat area | (cm2) | 386.8±59.1 | 392.8±59.8 |
| Systolic blood pressure | (mm Hg) | 124.4±17.7 | 125.5±17.9 |
| Diastolic blood pressure | (mm Hg) | 73.6±13.2 | 75.0±13.3 |
| Pulse rate | (beats/min) | 69.3±9.8 | 69.6±9.9 |
a
×±SD.
No significant difference was observed between groups.